Subject:
- Active Substance: Cerliponase alfa
- Name: Brineura®
- Therapeutic area: Neuronal ceroid lipofuscinosis type 2 (CLN2 disease)
- Pharmaceutical company: BioMarin Deutschland GmbH
Time table:
- Start: 01.07.2022
- Final decision by G-BA: 15.12.2022
Final decision:
- HInt for a major additional benefit